Becton, Dickinson and Company (NYSE:BDX) Releases FY 2026 Earnings Guidance

08 May 2026, 17:22 by Scott Moore · The Cerbat Gem

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 12.520-12.720 for the period, compared to the consensus estimate of 12.490. The company issued revenue guidance of -.

Becton, Dickinson and Company Stock Performance

BDX stock traded down $4.02 during midday trading on Friday, reaching $149.24. The company had a trading volume of 4,473,691 shares, compared to its average volume of 2,855,225. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The stock has a 50 day moving average price of $158.49 and a 200 day moving average price of $181.08. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The firm has a market capitalization of $42.49 billion, a PE ratio of 24.35, a P/E/G ratio of 10.32 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same period in the previous year, the firm posted $3.35 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts anticipate that Becton, Dickinson and Company will post 12.53 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is presently 68.52%.

Becton, Dickinson and Company declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

BDX has been the subject of several analyst reports. TD Cowen reduced their price target on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a report on Monday. Barclays initiated coverage on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a report on Friday, April 10th. They set a “neutral” rating and a $167.00 price target for the company. Wells Fargo & Company boosted their price target on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Friday. Finally, Piper Sandler reduced their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Seven equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $184.71.

View Our Latest Stock Report on Becton, Dickinson and Company

Insiders Place Their Bets

In related news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director owned 36,763 shares of the company’s stock, valued at $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 1,102 shares of company stock valued at $198,909 over the last three months. Corporate insiders own 0.40% of the company’s stock.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

Positive Sentiment: BD posted fiscal Q2 adjusted EPS of $2.90, beating estimates of $2.77, while revenue of $4.71 billion also topped expectations. The company said sales rose 5.2% year over year, helped by strength in drug-delivery devices and surgical equipment. BD Reports Second Quarter Fiscal 2026 Financial Results
Positive Sentiment: Management raised full-year FY 2026 adjusted EPS guidance to $12.52-$12.72, above the prior outlook and slightly ahead of consensus, reinforcing confidence in the company’s earnings trajectory. Becton Dickinson raises annual profit forecast on strength in drug delivery devices
Positive Sentiment: Evercore raised its price target on BDX to $190 from $180, and Wells Fargo lifted its target to $161 from $157, signaling improving sentiment after the earnings update. Evercore ISI Adjusts Price Target on Becton Dickinson and Company to 190 from 180
Neutral Sentiment: BD also appointed Vitor Roque as chief financial officer, a routine leadership change that is not likely to move the stock on its own. BD Appoints Vitor Roque Chief Financial Officer
Neutral Sentiment: Stifel cut its price target to $175 from $215, but the new target still implies upside, so the note appears more like a reset than a bearish call. Stifel Nicolaus Adjusts Becton Dickinson and Company Price Target to 175 from 215

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors have recently bought and sold shares of the stock. Cambient Family Office LLC acquired a new stake in Becton, Dickinson and Company in the fourth quarter worth about $217,000. Compound Planning Inc. raised its position in Becton, Dickinson and Company by 72.9% in the fourth quarter. Compound Planning Inc. now owns 2,887 shares of the medical instruments supplier’s stock worth $560,000 after acquiring an additional 1,217 shares in the last quarter. Invesco Ltd. raised its position in Becton, Dickinson and Company by 48.5% in the fourth quarter. Invesco Ltd. now owns 3,790,490 shares of the medical instruments supplier’s stock worth $735,620,000 after acquiring an additional 1,237,507 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its position in Becton, Dickinson and Company by 22.2% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 28,140 shares of the medical instruments supplier’s stock worth $5,461,000 after acquiring an additional 5,106 shares in the last quarter. Finally, Andrews Advisory Associates LLC bought a new stake in Becton, Dickinson and Company in the fourth quarter worth about $253,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

(Get Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.